Compare Moderna, Inc. (MRNA) vs Rush Street Interactive Inc (RSI) Price & Performance

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Rush Street Interactive (RSI) trades at $24.53, down 0.77% on the day, amid mixed technical signals with a bearish overall trend but oversold oscillators. The company reported strong Q2 2026 results with record revenue of $393.8 million and raised full-year guidance, though net margins remain thin at 2.33%. Analyst sentiment remains bullish with 77% buy ratings and a $34.75 consensus target.

RSI shows promising revenue growth and institutional interest but faces valuation concerns with a high P/E of 81.13. The stock offers significant upside to analyst targets but requires careful monitoring of margin expansion and competitive pressures in the online gambling sector.